


Express Mail Label No.: E1846328US

Date of Deposit: July 18, 2001

Attorney Docket No. 21486-038



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Calabresi et al.

SERIAL NUMBER: 09/802,094

EXAMINER: Unknown

FILING DATE: March 3, 2001

ART UNIT: 1614

FOR: COMBINATION DRUG THERAPY

RECEIVED
JUL 20 2001
TECH CENTER 1600/2900

July 18, 2001
Boston, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- ☒ Information Disclosure Statement (1 pg.);
- ☒ PTO Form 1449 (2 pgs.);
- ☒ Copy of references cited; and
- ☒ Return postcard.

Applicant believes that no fees are due with this submission; however, the Commissioner is hereby authorized to charge any fees that may be due to Deposit Account No. 50-0311, Reference No. 21486-038. A duplicate copy of this Transmittal Letter is enclosed.

Respectfully submitted,

IABeattie

Ivor R. Elrifi (Registration No. 39,529)

Ingrid A. Beattie (Registration No. 42,306)

Attorneys for the Applicant

c/o MINTZ, LEVIN

One Financial Center


Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

Express Mail Label No.: E1184328US
Date of Deposit: July 18, 2001

IDS/#5
8/15/02
Attorney Docket No. 21486-038



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
JUL 20 2001
TECH CENTER 1600/2900

APPLICANTS: Calabresi et al.
SERIAL NUMBER: 09/802,094 EXAMINER: Unknown
FILING DATE: March 3, 2001 ART UNIT: 1614
FOR: COMBINATION DRUG THERAPY

July 18, 2001
Boston, Massachusetts


Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is required. 37 C.F.R. §1.97. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21486-038.

Respectfully submitted,


Ivor R. Elrifi (Registration No. 39,529)
Ingrid A. Beattie (Registration No. 42,306)
Attorneys for the Applicant
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

RECEIVED

JUL 27 2001

TECH CENTER 1600/2900

Modified Form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT OF APPLICANT

(use as many sheets as necessary)

Application Number	09/802,094
Filing Date	March 3, 2001
First Named Inventor	Paul Calabresi
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	21486-038

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	AA	6,100,273	8/8/00	Besterman et al.	514	279	
	AB	5,192,744	3/9/93	Bouck et al.	514	8	
	AC	5,840,692	11/24/98	Deutch et al.	514	12	

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	BA	WO 9954445 A2	Joshi et al.	10/24/99	
	BB	WO 9910525 A1	Heimbrook et al.	03/04/99	
	BC	WO 9910524 A1	Burkhardt et al.	03/04/99	
	BD	WO 9910523 A1	Barnett et al.	03/04/99	
	BE	WO 9843618 A2	Kunz et al.	10/08/98	
	BF	WO 9601127 A1	Ratain et al.	01/18/96	

OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	CA	Clements et al., "Antiangiogenic potential of camptothecin and topotecan," 1999, Cancer Chemotherapy and Pharmacology, V44, N1, p. 39-48.
	CB	Clements et al., "Inhibition of Angiogenesis and Proliferation of Normal Endothelial Cells by Camptothecin," 1998, FASEB J., N5, 2, S(March 20), p. 5499
	CC	Clements et al., "Camptothecin exhibits selective cytotoxicity towards human breast carcinoma as compared to normal bovine endothelial cells <i>in vitro</i> ," 1996, Anticancer Drugs 7:851.
	CD	Guo et al., "Thrombospondin 1 and Type I Repeat Peptides of Thrombospondin 1 Specifically Induce Apoptosis of Endothelial Cells," Cancer Res. 57/9 (1735-1742).
	CE	Hsiang et al., "DNA Topoisomerase I-mediated DNA Cleavage and Cytotoxicity of Camptothecin Analogues," 1989, Cancer Research, 49:4385-4389.
	CF	Jaxel et al., "Structure-Activity Study of the Actions of Camptothecin Derivatives on Mammalian Topoisomerase I: Evidence for a Specific Receptor Site and a Relation to Antitumor Activity," Cancer Research, 49:1465-1469.
	CG	Kakeji et al., "Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents," Investigational New Drugs, 7(1):39-48
Examiner Signature		Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/802,094
	Filing Date	March 3, 2001
	First Named Inventor	Paul Calabresi
	Group Art Unit	1614
	Examiner Name	Unknown
	Attorney Docket Number	21486-038

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	AD	5,994,309	09/30/99	Mazar et al.	514	16	
	AE	5,994,341	09/30/99	Hunter et al.	514	210	
	AF	5,981,568	09/09/99	Kunz et al.	514	411	
	AG	5,886,026	03/23/99	Hunter et al.	514	449	
	AH	5,843,994	12/01/98	Samid	514	510	
	AI	5,786,344	07/28/98	Ratain et al.	514	100	
	AJ	5,670,507	09/23/97	Rice et al.	514	263	

OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	CH	Kantarjian et al., "New Developments in the Treatment of Acute Myeloid Leukemia: Focus on Topotecan," Seminars in Hematology, 36/4 Suppl. 8 (16-5).
	CI	O'Leary et al., "Antiangiogenic Effects of Camptothecin Analogues 9-Amino-20(S)-camptothecin, Topotecan, and CPT-11 Studies in the Mouse," 1999, Clinical Cancer Research, 5:181-7
	CJ	Polverini et al., "Assay and Purification of Naturally Occurring Inhibitor of Angiogenesis," 1991, Methods. Enzymol. 198:440-450.
Examiner Signature		Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.